Published in Clin Dev Immunol on September 13, 2010
Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol (2009) 12.98
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med (2006) 8.39
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis (2005) 6.59
The mortality and pathology of HIV infection in a west African city. AIDS (1993) 6.08
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis (2008) 5.94
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis (2007) 5.40
Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev (2010) 4.95
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet (2010) 4.95
HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med (2009) 4.76
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis (2010) 4.56
Immune restoration disease after antiretroviral therapy. AIDS (2004) 4.54
HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet (2001) 4.33
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
Natural ventilation for the prevention of airborne contagion. PLoS Med (2007) 3.73
Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med (1998) 3.64
Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis (2009) 3.37
Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ (1982) 3.34
Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med (1995) 3.09
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS (2009) 3.06
Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS (2005) 2.96
Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev (2004) 2.95
Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis (2007) 2.79
Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet (2000) 2.77
Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis (2004) 2.56
Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis (2003) 2.49
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS (1998) 2.35
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS (2005) 2.28
Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis (2007) 2.28
The immune reconstitution inflammatory syndrome. AIDS Rev (2003) 2.22
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ (2006) 2.13
Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. Clin Infect Dis (2010) 2.10
Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis (1997) 2.07
Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One (2010) 2.03
Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa. AIDS (2001) 1.97
Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr (2004) 1.97
Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy : pathogenesis, clinical manifestations and management. Drugs (2008) 1.95
Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis (2008) 1.94
Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis (2009) 1.92
Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis (2009) 1.92
Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology (1994) 1.87
Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr (1991) 1.85
Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis (2009) 1.78
Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis (2010) 1.66
Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med (2009) 1.64
Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies. Trop Med Int Health (2005) 1.63
Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med (2000) 1.55
Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr (2008) 1.49
Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis (2007) 1.49
Control and prevention of healthcare-associated tuberculosis: the role of respiratory isolation and personal respiratory protection. J Hosp Infect (2007) 1.48
Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?' AIDS, 22 July 2005. AIDS (2005) 1.45
Preventive therapy against tuberculosis in people living with HIV. Wkly Epidemiol Rec (1999) 1.41
Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges. Can J Infect Dis Med Microbiol (2008) 1.40
Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. J Acquir Immune Defic Syndr (2010) 1.37
Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS (2001) 1.28
Protecting health care workers from SARS and other respiratory pathogens: a review of the infection control literature. Am J Infect Control (2005) 1.25
Monitoring human exposures to upper-room germicidal ultraviolet irradiation. J Occup Environ Hyg (2005) 1.22
Risk factors for negative sputum acid-fast bacilli smears in pulmonary tuberculosis: results from Dakar, Senegal, a city with low HIV seroprevalence. Int J Tuberc Lung Dis (1999) 1.20
Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group. Arch Intern Med (1995) 1.14
Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa. Int J Gynaecol Obstet (2010) 1.08
Treatment Options for HIV-Associated Tuberculosis. J Infect Dis (2007) 1.07
Protecting health care workers from SARS and other respiratory pathogens: organizational and individual factors that affect adherence to infection control guidelines. Am J Infect Control (2005) 1.06
Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings. J Int Assoc Physicians AIDS Care (Chic) (2010) 1.05
The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis (2000) 1.04
HIV, BCG and TB in children: a case control study in Lusaka, Zambia. J Trop Pediatr (1993) 1.03
Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS (1997) 0.96
Reflections on the white plague. Lancet Infect Dis (2009) 0.90
HIV-associated maternal mortality--primary causes of death at King Edward VIII Hospital, Durban. S Afr Med J (2007) 0.88
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31
XDR-TB in South Africa: no time for denial or complacency. PLoS Med (2007) 4.20
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med (2012) 2.48
High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med (2010) 2.23
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med (2005) 2.06
Global development. Family planning and the Millennium Development Goals. Science (2010) 1.78
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis (2012) 1.73
Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal, South Africa. Ann Thorac Surg (2012) 1.40
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis (2013) 1.37
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother (2012) 1.33
The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med (2012) 1.32
The changing epidemiology of HIV in 2013. Curr Opin HIV AIDS (2013) 1.31
The whole is greater than the sum of the parts: recognising missed opportunities for an optimal response to the rapidly maturing TB-HIV co-epidemic in South Africa. BMC Public Health (2009) 1.26
Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis (2004) 1.18
Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis (2012) 1.17
Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect Dis (2013) 1.12
Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Glob Public Health (2014) 1.12
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol (2010) 1.11
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav (2014) 1.09
Global epidemiology of HIV-AIDS. Infect Dis Clin North Am (2007) 1.06
Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav (2014) 1.06
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials (2011) 1.04
HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. BMC Public Health (2012) 1.04
Interventions to modify sexual risk behaviours for preventing HIV in homeless youth. Cochrane Database Syst Rev (2011) 0.98
Social constraints to TB/HIV healthcare: accounts from coinfected patients in South Africa. AIDS Care (2012) 0.98
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr (2012) 0.97
Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. AIDS (2012) 0.96
Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study. J Acquir Immune Defic Syndr (2014) 0.95
Antiretroviral therapy: challenges and options in South Africa. Lancet (2003) 0.91
Extensively drug-resistant tuberculosis in women, KwaZulu-Natal, South Africa. Emerg Infect Dis (2011) 0.89
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol (2013) 0.87
The preventive misconception: experiences from CAPRISA 004. AIDS Behav (2014) 0.86
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. S Afr Med J (2010) 0.85
Health-care workers' perspectives on workplace safety, infection control, and drug-resistant tuberculosis in a high-burden HIV setting. J Public Health Policy (2013) 0.85
Trends in HIV Prevalence in Pregnant Women in Rural South Africa. J Acquir Immune Defic Syndr (2015) 0.84
Experience in international clinical research: the HIV Prevention Trials Network. Clin Investig (Lond) (2011) 0.84
Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004. J Acquir Immune Defic Syndr (2013) 0.83
Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis. IRB (2011) 0.82
The HIV epidemic in Southern Africa - Is an AIDS-free generation possible? Curr HIV/AIDS Rep (2014) 0.82
Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial. Antivir Ther (2013) 0.80
The contrasting cultures of HIV and tuberculosis care. AIDS (2015) 0.79
Vertical HIV transmission in South Africa: translating research into policy and practice. Lancet (2002) 0.79
Managing multiple and extensively drug-resistant tuberculosis and HIV. Expert Opin Pharmacother (2007) 0.79
Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study. AIDS Behav (2014) 0.79
Diverse approaches useful for microbicide trials. Nature (2007) 0.79
Implementing microbicides in low-income countries. Best Pract Res Clin Obstet Gynaecol (2012) 0.78
Anti-retrovirals for treatment and prevention--time for new paradigms in our response to the HIV/AIDS epidemic? Dev World Bioeth (2013) 0.77
Metabolic Syndrome After HIV Acquisition in South African Women. J Acquir Immune Defic Syndr (2016) 0.77
Antibodies for HIV prevention in young women. Curr Opin HIV AIDS (2015) 0.77
High rates of tuberculosis in patients accessing HAART in rural South Africa. J Acquir Immune Defic Syndr (2014) 0.77
Early evolution of HLA-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C infected women. AIDS (2016) 0.75
Prevention of HIV by male circumcision. BMJ (2007) 0.75
Tenofovir Gel to Prevent HSV-2 Infection. N Engl J Med (2015) 0.75
Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial. Antiviral Res (2013) 0.75
Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr (2015) 0.75
Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women. J Acquir Immune Defic Syndr (2017) 0.75
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. AIDS (2017) 0.75
The power of HIV/AIDS epidemiology. Curr Opin HIV AIDS (2009) 0.75
A community officer's perspective of a rural hospital in KwaZulu-Natal. S Afr Med J (2012) 0.75
Treat the patient, not the result. S Afr Med J (2009) 0.75
Genital - Systemic chemokine gradients and the risk of HIV acquisition in women. J Acquir Immune Defic Syndr (2016) 0.75
Meeting the sexual and reproductive health needs of high-school students in South Africa: experiences from rural KwaZulu-Natal. S Afr Med J (2014) 0.75
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. J Antimicrob Chemother (2017) 0.75
Bedaquiline adherence measured by electronic dose monitoring predicts clinical outcomes in the treatment of patients with multidrug-resistant tuberculosis and HIV/AIDS. J Acquir Immune Defic Syndr (2022) 0.75
Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide. J Acquir Immune Defic Syndr (2017) 0.75